Meteor Biotech, which works in spatially resolved cell isolation technologies for advanced biomedical research, is set to participate in a life sciences project in South Korea: ‘Development of Core Technology for the Commercialization of Brain Organoids’, a seven-year, $10m national initiative led by Sungkyunkwan University (SKKU) and supported by the Ministry of Science and ICT.
Brain organoids are miniature, stem cell-derived human brain models that replicate the key features of brain development and disease. They are increasingly recognised as a promising alternative to animal testing and as a powerful platform for improving the understanding of neurodegenerative disorders, such as Alzheimer’s, and evaluating new therapeutics.
The South Korean Government recently selected the project as a key initiative under its Bio and Medical Technology Development Program. Led by Jong-Chan Park of SKKU, the consortium brings together organisations from academia, regulatory science and biotechnology. Meteor Biotech joins Next&Bio, a developer of patient-derived organoid technologies and microphysiological systems for drug screening, precision medicine and cell therapy development; Central Bio, a contract research organisation and testing services company; Cellartgen, a biotech company focused on regenerative medicine, organoids and advanced biomaterials; the Korea Brain Research Institute (KBRI) and the Korea Institute of Toxicology (KIT).
The consortium aims to overcome major barriers in the commercialisation of brain organoids, including manufacturing standardisation, scalability, immune functionality, quality control, transportation and analytical validation. Over the next seven years, the partners will work towards setting the standards for the world’s first integrated commercialisation platform for advanced brain organoids. They will support the widespread use of brain organoids in disease research, drug discovery, toxicity testing and precision medicine.
“Brain organoids are powerful because their biology is inherently spatial,” said Amos Lee, CEO at Meteor Biotech.
“The disease relevance of an organoid depends not only on which cells are present, but also on where they are located and how they interact within a three-dimensional structure. The next challenge for the field is to move beyond simply observing spatial patterns and to begin selecting the cells and microenvironments that truly drive disease biology.”
As part of this initiative, Meteor Biotech will contribute its proprietary SLACS (spatially-resolved laser activated cell sorting) technology, enabling researchers to selectively isolate spatially defined cellular populations directly from tissue sections, while preserving tissue context from brain organoids for downstream molecular analysis.
“SLACS is uniquely positioned to support this transition by helping researchers transform spatial information into recoverable, analysable cells for deeper molecular investigation. Through this project, Meteor Biotech is proud to contribute to the development of scalable, biologically precise brain organoid platforms that will accelerate disease modelling, therapeutic discovery and precision medicine,” Lee said.
Unlike conventional approaches that, in the act of dissociating tissues into single cells, lose the spatial information that dictates so much of cellular fate and function, SLACS allows researchers to recover individual cells or spatially defined regions based on their biological relevance. This capability enables deeper investigation of disease-driving cellular interactions, immune responses and treatment mechanisms within increasingly complex organoid systems.